SCHEMBL6437306

SCHEMBL6437306

O=C1CCCC2=C1C(c1cccc(OC(F)(F)F)c1)C1=C(CCS1(=O)=O)N2

nearest known ligand 0.68

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ABCC9 O60706 20/20 0.68
ABCC8 Q09428 20/20 0.68
KCNJ11 Q14654 20/20 0.68
KCNJ8 Q15842 20/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6432657 0.93 ABCC9 (0.60) ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL6433306 0.88 ABCC9 (0.66) ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL7824118 0.88 ABCC9 (0.63) ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL7824114 0.83 ABCC9 (0.58) ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL6435701 0.82 ABCC9 (0.58) ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL6434792 0.80 ABCC9 (0.71) ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL6468926 0.79 ABCC9 (0.55) ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL6437342 0.78 ABCC9 (1.00) ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL7242760 0.78 ABCC9 (1.00) ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL7234774 0.78 ABCC9 (0.79) ABCC9ABCC8KCNJ11KCNJ8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1194429-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2005-03-30 EP claimed
US-6593335-B1 Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's ABBOTT LABORATORIES 2003-07-15 US claimed
EP-1194429-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2005-03-30 EP disclosed
US-6593335-B1 Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's ABBOTT LABORATORIES 2003-07-15 US disclosed
EP-1194429-A1 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2002-04-10 EP disclosed
WO-2000078768-A1 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2000-12-28 WO disclosed